Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Caregiver burden — and burnout — is one of the least talked about aspects of these devastating diseases. But it is very real.

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for schizophrenia.

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

For some patients, simulated situations controlled by therapists may be less overwhelming than real-life exposure therapy.

were expected to provide better effectiveness and promote adherence in patients with schizophrenia. This study was implemented to assess the efficacy and safety of once-daily quetiapine XR in ...

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in ... difference in response” in patients whose background therapy ...